Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05724810 · ClinicalTrials.gov registry record · NA
Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia
A NA study of Schizophrenia and Smoking Cessation, sponsored by Stony Brook University.
- Recruiting
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT05724810: Recruiting NA study of Schizophrenia and Smoking Cessation, sponsored by Stony Brook University.
NCT05724810 is a NA study of Schizophrenia and Smoking Cessation that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 38 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05724810, a NA study of Schizophrenia and Smoking Cessation, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose of the study: Evaluate the effect of deep repetitive transcranial magnetic stimulation (deep rTMS; hereafter abbreviated as "dTMS") on synaptic density measured with positron emission tomography (PET) and the radiotracer \[11C\]UCB-J. The investigators also seek to link plasticity changes in the regions targeted by the electric field (especially, the insula) to changes in the functioning of insula circuits and behavioral cigarette usage in patients with schizophrenia (SCZ). Importance of the study: This is the first study designed to directly evaluate the mechanism of action (MOA) of dTMS for smoking disruption in patients with SCZ. Patients with SCZ are a vulnerable population in high, immediate need of new smoking therapeutics for reducing premature morbidity and mortality.
Primary Outcome
PET with UCB-J will be used to look at synaptic density pre/post intervention
Conditions Studied
Interventions
- DEVICE Active deep transcranial magnetic stimulation (dTMS)
- DEVICE Sham dTMS
Study Locations (1)
New York
- Stony Brook University - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2028-08-31 |
| Phase | NA |
What NCT05724810 shows while recruiting
NCT05724810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Active deep transcranial magnetic stimulation (dTMS) is the first listed.
NCT05724810 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05724810 about?
NCT05724810 is a clinical study titled "Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia". Purpose of the study: Evaluate the effect of deep repetitive transcranial magnetic stimulation (deep rTMS; hereafter abbreviated as "dTMS") on synaptic density measured with positron emission tomography (PET) and the radiotracer \[11C\]UCB-J. The investigators also seek to link plasticity changes in...
What is the current status of trial NCT05724810?
This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2023-04-04. Estimated completion is 2028-08-31.
What conditions does trial NCT05724810 study?
This clinical trial studies the following conditions: Schizophrenia, Smoking Cessation, Tobacco Use.
What interventions are being tested in trial NCT05724810?
The interventions under investigation include: Active deep transcranial magnetic stimulation (dTMS) (DEVICE), Sham dTMS (DEVICE).
Who is sponsoring clinical trial NCT05724810?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05724810 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05724810's enrollment target sits among peer trials
38 246th of 315 higher than 66 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI